[Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome].
OBJECTIVE
To evaluate the clinical efficacy and safety of dexketoprofen trometamol in the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).


METHODS
A total of 115 patients with CP/CPPS were divided into a dexketoprofen trometamol group (n = 40), treated with dexketoprofen trometamol (25 mg, tid) and terazosin (2 mg, qn), an indometacin group (n = 40) given indometacin (25 mg, tid) and terazosin (2 mg, qn), and a terazosin group (n = 35) administered terazosin (2 mg, qn) only, all treated for 4 weeks. Scores on the NIH-chronic prostatitis symptom index (NIH-CPSI) were obtained before and after the treatment, and the efficacy and adverse events were observed and compared.


RESULTS
The NIH-CPSI scores were significantly improved after the treatment in all the three groups. The clinical efficacy was significantly better in the dexketoprofen trometamol and indometacin groups than in the terazosin group (P < 0.05), but with no significant difference between the former two (P > 0.05). The rates of adverse events were 10.00%, 18.57% and 27.50% in the dexketoprofen trometamol, terazosin and indometacin groups, significantly lower in the former two than in the latter one (P < 0.05).


CONCLUSIONS
The combination of dexketoprofen trometamol with terazosin could effectively improve the clinical symptoms of CP/CPPS, better than terazosin in therapeutic efficacy and than indometacin in drug tolerance.
Jiang
Ming-hua
MH
Department of Venereology, Hengli People's Hospital, Dongguan, Guangdong 523460, China. jmh5270@sina.com
Wu
Guan-cheng
GC
Liu
Hong-liang
HL
D000328:Adult; D002908:Chronic Disease; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000627:therapeutic use; D007660:Ketoprofen / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D017699:Pelvic Pain / Q000188:drug therapy*; D011224:Prazosin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D011472:Prostatitis / Q000188:drug therapy*; D014325:Tromethamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014325:Tromethamine; C041226:Terazosin; D007660:Ketoprofen; C118296:dexketoprofen trometamol; D011224:Prazosin; D007213:Indomethacin